This invention relates to a method and composition for balancing the bile acid profile in the intestine of humans, particularly decreasing primary bile acids and/or increasing production of secondary bile acids.

This invention relates to a method and composition for balancing the bile acid profile in the intestine of humans, particularly decreasing primary bile acids and/or increasing production of secondary bile acids.

The present invention relates to the development of a targeted delivery system for the oral delivery of probiotics or therapeutic agent for various indications, including and not limited to active and prophylaxis treatment of Clostridium difficile infection, antibiotic associated diarrhea, irritable bowel syndrome, Crohn's disease, intestinal flora replacement, supplemental flora treatments for patients taking antibiotics, and for restoration of balance and signaling between the intestinal microbiome and the intestinal cells in patients under treatment of metabolic syndrome manifestations, specifically diabetes, insulin resistance, obesity, hyperlipidemia and hypertension. The present invention restores altered probiotic organism imbalances that are characteristic of said diseases among others as well as defines a platform technology development for site specific delivery of probiotic organisms in the GI tract of a mammal, most specifically the ileum and/or right colon of a human subject.

The present invention relates to a pharmaceutical composition which contains activated charcoal, Carum carvi extract, papain and, optionally, α-galactosidase and β-galactosidase for the treatment of gastrointestinal disorders.

The present invention relates to a pharmaceutical composition which contains activated charcoal, Carum carvi extract, papain and, optionally, α-galactosidase and β-galactosidase for the treatment of gastrointestinal disorders.

The present application relates to methods for treatment of bacteria and viruses with C.sub.2-C.sub.7 alkyl boronic acids to reduce growth and virulence.

The present application relates to methods for treatment of bacteria and viruses with C.sub.2-C.sub.7 alkyl boronic acids to reduce growth and virulence.

Provided is a use of fibers formed of β-1-4-glucan in manufacturing a composition for preventing or treating diarrhea, constipation or irritable bowel syndrome, wherein the fibers have a diameter between 15 nm to 35 nm and a mean length of between 1.5 μm and 3.5 μm. Also provided is a method for preventing or treating diarrhea, constipation or irritable bowel syndrome with the fibers formed of β-1-4-glucan.

Provided is a use of fibers formed of β-1-4-glucan in manufacturing a composition for preventing or treating diarrhea, constipation or irritable bowel syndrome, wherein the fibers have a diameter between 15 nm to 35 nm and a mean length of between 1.5 μm and 3.5 μm. Also provided is a method for preventing or treating diarrhea, constipation or irritable bowel syndrome with the fibers formed of β-1-4-glucan.

The disclosures herein relate to novel compounds of formula ##STR00001##
wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.